{"protocolSection": {"identificationModule": {"nctId": "NCT03662126", "orgStudyIdInfo": {"id": "KRT-232-101"}, "organization": {"fullName": "Kartos Therapeutics, Inc.", "class": "INDUSTRY"}, "briefTitle": "KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment", "officialTitle": "A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT 232 in Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post-PV-MF), Or Post Essential Thrombocythemia MF (Post-ET-MF) Who Are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment", "acronym": "BOREAS"}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Kartos Therapeutics, Inc.", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with myelofibrosis (MF) who no longer benefit from treatment with a JAK inhibitor. Inhibition of MDM2 is a novel mechanism of action in MF.\n\nThis study will be conducted in 2 phases. Phase 2 will determine the KRT-232 recommended dose and dosing schedule; Phase 3 will test KRT-232 vs Best Available Therapy (BAT). Patients in the Phase 3 part of the study will be randomized 2:1 to receive either KRT-232 (Arm 1) or BAT (Arm 2). The BAT administered will be determined by the treating physician, with the option to \"cross-over\" to KRT-232 treatment after 6 months of BAT or if the disease worsens at any time."}, "conditionsModule": {"conditions": ["Primary Myelofibrosis (PMF)", "Post-Polycythemia Vera MF (Post-PV-MF)", "Post-Essential Thrombocythemia MF (Post-ET-MF)"], "keywords": ["navtemadlin"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2", "PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "SINGLE", "whoMasked": ["OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 385, "type": "ESTIMATED"}}, "armsInterventionsModule": {"armGroups": [{"label": "Part A Cohort 1", "type": "EXPERIMENTAL", "description": "KRT-232 120 mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)", "interventionNames": ["Drug: KRT-232"]}, {"label": "Part A Cohort 2", "type": "EXPERIMENTAL", "description": "KRT-232 240 mg by mouth once daily for Days 1-7, off treatment for Days 8-21 (21-day cycles)", "interventionNames": ["Drug: KRT-232"]}, {"label": "Part A Cohort 3", "type": "EXPERIMENTAL", "description": "KRT-232 240 mg by mouth once daily for Days 1-7, off treatment for Days 8-28 (28-day cycles)", "interventionNames": ["Drug: KRT-232"]}, {"label": "Part A Cohort 4b", "type": "EXPERIMENTAL", "description": "KRT-232 240 mg by mouth once daily for Days 1-5, off treatment for Days 6-28 (28-day cycles)", "interventionNames": ["Drug: KRT-232"]}, {"label": "Part B Arm 1 KRT-232", "type": "EXPERIMENTAL", "description": "KRT-232 240 mg by mouth once daily for Days 1-7, off treatment for Days 8-28 (28-day cycles)", "interventionNames": ["Drug: KRT-232"]}, {"label": "Part B Arm 2 Best Available Therapy", "type": "ACTIVE_COMPARATOR", "description": "Best available therapy at the discretion of the investigator, on a 28-day cycle.", "interventionNames": ["Drug: Best Available Therapy (BAT)"]}], "interventions": [{"type": "DRUG", "name": "KRT-232", "description": "KRT-232, administered by mouth", "armGroupLabels": ["Part A Cohort 1", "Part A Cohort 2", "Part A Cohort 3", "Part A Cohort 4b", "Part B Arm 1 KRT-232"]}, {"type": "DRUG", "name": "Best Available Therapy (BAT)", "description": "Best available therapy options include:\n\n1. hydroxyurea\n2. chemotherapy or\n3. supportive care (including but not limited to corticosteroids and androgens; JAK inhibitors not allowed).", "armGroupLabels": ["Part B Arm 2 Best Available Therapy"]}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Confirmed diagnosis of PMF, post-PV MF or post-ET MF (WHO)\n* High, intermediate-2, or intermediate-1 risk Dynamic International Prognostic System (DIPSS)\n* Failure of prior treatment with JAK inhibitor\n* ECOG \u2264 2\n\nExclusion Criteria:\n\n* Prior splenectomy\n* Splenic irradiation within 3 months prior to randomization\n* History of major hemorrhage or intracranial hemorrhage within 6 months prior to randomization\n* History of stroke, reversible ischemic neurological defect or transient ischemic attack within 6 months prior to randomization\n* Prior MDM2 inhibitor therapy or p53-directed therapy\n* Prior allogeneic stem-cell transplant or plans for allogeneic stem cell transplant\n* History of major organ transplant\n* Grade 2 or higher QTc prolongation (\\> 480 milliseconds per NCI-CTCAE criteria, version 5.0)", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"centralContacts": [{"name": "John Mei", "role": "CONTACT", "phone": "650-542-0136", "email": "jmei@kartosthera.com"}, {"name": "Yulia Khalina", "role": "CONTACT", "phone": "908-656-2799", "email": "ykhalina@kartosthera.com"}]}, "referencesModule": {"references": [{"type": "BACKGROUND", "citation": "Al-Ali, H.K.; Delgado, R.G.; Lange, A.; Pluta, A.; McLornan, D.; Vachhani, P.; Damaj, G.L.; Jost, P.J.; Rejto, L.; Hus, M.; et al. KRT-232, A First-In-Class, Murine Double Minute 2 Inhibitor, for Myelofibrosis Relapsed or Refractory to Janus-Associated Kinase Inhibitor Treatment. Eha. Libr. 2020, 295035, S215"}]}}, "hasResults": false}